Amgen backs States’ efforts to enact biosimilar legislation that allows for substitution and supports patient safety
25 January 2013 | By Amgen
"Amgen endorses state policies that would put patients first..."
List view / Grid view
News
Heinrich Meintrup becomes Group Managing Director of GEA Pharma Systems
24 January 2013 | By The Words Workshop Ltd
On 1 January 2013 Heinrich Meintrup took over his new role as Group Managing Director...
Anders Hamsten to be installed as new president of Karolinska Institutet
24 January 2013 | By Cision
“Anders Hamsten will be an excellent president. It is also very gratifying that he has solid support from within the organisation”
FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
24 January 2013 | By Roche
Roche announced that the US FDA approved a new use of Avastin...
Pfizer announces top-line efficacy results from a Phase 4 study of PRISTIQ® (desvenlafaxine)
24 January 2013 | By Pfizer
New data add to evidence supporting PRISTIQ as a treatment option for MDD...
GSK appoints Hans Wijers to its Board as a Non-Executive Director
24 January 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013...
Gilead initiates Phase 3 clinical program for tenofovir alafenamide
24 January 2013 | By Gilead Sciences
“We are pleased to move TAF into Phase 3 clinical research...”
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
24 January 2013 | By Biogen Idec
Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial...
Novartis drug Exjade® first treatment approved by FDA
23 January 2013 | By Novartis
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia...
Recent advances in Microbiology – Rapid Mycoplasma Test
22 January 2013 | By SMi Group
SMi’s Pharmaceutical Microbiology conference taking place on the 30th & 31st January London...
ABRAXANE® (nab-paclitaxel) plus gemcitabine demonstrates survival advantage in Phase III study of patients with advanced pancreatic cancer1
22 January 2013 | By Weber Shandwick
Celgene UK and Ireland announced that its phase III clinical trial of ABRAXANE® (nab-paclitaxel) in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival...
Automated buffy coat isolation on Tecan’s Freedom EVO®
22 January 2013 | By kdm communications
Tecan and IBBL have co-developed an automated platform for buffy coat extraction based on a Freedom EVO® 200 workstation...
Pfizer partnership organizations significantly benefit from Pfizer’s Global Health Fellows Program
22 January 2013 | By Pfizer
Pfizer celebrates 10th anniversary of this signature social investment program...
Novartis receives EU approval for Bexsero®
22 January 2013 | By Novartis
Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe...
GSK signs up to UK Government’s Public Health Responsibility Deal
22 January 2013 | By GlaxoSmithKline
As a global healthcare company, at GSK we believe we have a responsibility to help people make healthier choices...
